Replies to post #123839 on Biotech Values

[ghmm]

Ohad Hammer has a very impressive portfolio. What is interesting is there are 4 negative positions in it... and 3 are Array!

[vinmantoo]

mcbio,

Thanks for the very informative post. I do own some IMGN and have more than doubled my initial stake, but have concerns about future growth given the low royalty rate. If I had any brains, I would think about lighten up now, but might wait a bit longer.

I do like the mention of PGNX at the end of the story that Hammer is opening a position in it. I have owned too much of it for a long time and it has been an anchor around my neck/wallet. I like the deal PGNX struck with Salix a few months ago. with and the payoff should be coming in then next year. I listen to the new PGNX CEO Mark Baker in a recent investor conference and he said that Relistor is being looked at for partnerships in Europe. What surprised and delighted me was that outside the US there would be a 60%-40% split of revenues with Salix, but in PGNX's favor. Something in Europe might happen later this year. I had a chance to make some nice money but failed to pull the trigger on that a few years ago. I have to learn when to sell off portions of my investments when I get the chance to lock in profits.